


Applicant : Or et al.
 Serial Number : 09/800,856
 Filed : March 5, 2001
 Page : 2

In the claims:


Please amend the claims as follows:

1. (Currently Amended) A cyclosporin represented by the formula



wherein

A is



X is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-;

Y is selected from the group consisting of:

- (i) C(O)-O-R1, where R1 is hydrogen, C1-C6 alkyl, which is substituted with halogen, heterocyclic, aryl, C1-C6-alkoxy, C1-C6 alkylthio, halogen-substituted C1-C6 alkoxy, or halogen-substituted C1-C6 alkylthio;
- (ii) C(O)-S-R1, where R1 is as previously defined;
- (iii) C(O)-OCH2-OC(O)R2, where R2 is C1-C6 alkyl, optionally substituted with halogen, C1-C6 alkoxy, C1-C6 alkylthio, heterocyclic or aryl;
- (iv) C(S)-O-R1, where R1 is as previously defined; and
- (v) C(S)-S-R1, where R1 is as previously defined;

Applicant : Or et al.
 Serial Number : 09/800,856
 Filed : March 5, 2001
 Page : 3

B is $-\alpha\text{Abu-}$, $-\text{Val-}$, $-\text{Thr-}$ or $-\text{Nva-}$; and

U is $-(\text{D})\text{Ala-}$, $-(\text{D})\text{Ser-}$, $-\text{[O-(2-hydroxyethyl)(D)Ser]-}$, $-\text{[O-acyl(D)Ser]-}$ or $-\text{[O-(2-acyloxyethyl)(D)Ser]-}$,

or a pharmaceutically acceptable salt thereof.

2. (Previously Amended) A cyclosporin according to claim 1 wherein B is $-\alpha\text{Abu-}$, and U is $-(\text{D})\text{Ala-}$.

3. (Currently Amended) A cyclosporin according to claim 1, wherein B is $-\alpha\text{Abu-}$, U is $-(\text{D})\text{Ala-}$,

X is absent, and Y is selected from a group consisting of:

C(O)-O-R1 where R1 is hydrogen, C1-C6 alkyl, which is substituted with halogen, heterocyclic, aryl, C1-C6-alkoxy, C1-C6-alkylthio, halogen- substituted C1-C6 alkoxy, or halogen-substituted C1-C6 alkylthio;

C(O)-S-R1 where R1 is as previously defined;

$\text{C(O)-OCH}_2\text{-OC(O)R2}$ where R2 is C1-C6 alkyl, optionally substituted with halogen, C1-C6-alkoxy, C1-C6-alkylthio, heterocyclic or aryl.

4. (Previously Amended) A cyclosporin according to claim 1 which is selected from the group consisting of:

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = COOCH_2Ph ;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = COOCH_2F ;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = COOCHF_2 ;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = COOCF_3 ;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = $\text{COOCH}_2\text{CF}_3$;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = COOCH_2Cl ;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = $\text{COOCH}_2\text{OCH}_3$;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = $\text{COOCH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = $\text{C(O)SCH}_2\text{Ph}$;

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is $-\text{CH}_2\text{CH}_2\text{CH}_2-$, Y = COOCH_3 ; and

Applicant : Or et al.
Serial Number : 09/800,856
Filed : March 5, 2001
Page : 4

Compound of Formula (I) wherein B = $-\alpha\text{Abu-}$, U = $-(\text{D})\text{Ala-}$, X is absent, Y = COOFmoc.

Please cancel claims 5-7.

8. (Original) A pharmaceutical composition for topical administration comprising a cyclosporin compound of claim 1 together with a pharmaceutically acceptable diluent or carrier therefor.

9. (Original) A method for treating inflammatory or obstructive airways disease in a subject in need of said treatment, which comprises topically administering to said subject a therapeutically effective amount of a cyclosporin compound of claim 1.

10. (Original) The method of claim 9 wherein said step of topically administering is by inhalation.

11. (Currently Amended) The method of claim 9, wherein said airways disease is asthma, allergic rhinitis, bronchitis, ~~GOPD~~chronic obstructive pulmonary disease, chronic bronchitis or cystic fibrosis.